Sufentanil sublingual - AcelRx

Drug Profile

Sufentanil sublingual - AcelRx

Alternative Names: ARX-01; ARX-02; ARX-04; ARX-F01; ARX-F02; DSUVIA; Dzuveo; Sublingual sufentanil; Sufentanil sublingual - NanoTab; Zalviso

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AcelRx Pharmaceuticals
  • Developer AcelRx Pharmaceuticals; Grunenthal
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acute pain; Postoperative pain

Highest Development Phases

  • Marketed Acute pain

Most Recent Events

  • 02 Aug 2018 AcelRx Pharmaceuticals expects FDA advisory committee meeting for DSUVIA in late Q3/early Q4 2018
  • 02 Aug 2018 AcelRx Pharmaceuticals expects re-submission of NDA for Zalviso® (sufentanil sublingual tablet system, 15mcg) in Q4 2018
  • 28 Jun 2018 Registered for Acute pain in European Union, Norway, Liechtenstein, Iceland (Sublingual) (Tablet, 30mcg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top